Hims & Hers shocks with Q1 loss as GLP-1 write-downs bite, but Novo deal lifts FY outlook
Q1 revenue of $608.1M missed expectations and the company swung to a 40c/share loss versus 4c profit forecast, sending shares down 12% to $25.55. ARPU slipped to $80 from $85. Despite the miss, management raised FY guide to $2.8B-$3B on a Wegovy partnership with Novo Nordisk and international expansion, targeting profitability by 2027.
Hims & Hers missed Q1 revenue and posted surprise loss on GLP-1 write-downs and legal costs; raised FY guide on Novo Nordisk Wegovy partnership and international growth, eyes peptides if FDA eases restrictions.
Why this matters
Hims & Hers takes GLP-1 write-downs as compounded semaglutide rules tighten, but pivots to a Wegovy partnership with Novo Nordisk to anchor its weight-loss roadmap and 2027 profitability target.
Retail-company signals steady at 203 over the past 90 days.